Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor,
Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor 
Growth
¬† 
F. Michael Yakes, Jason Chen, Jenny Tan, et al. 
¬† 
Mol Cancer Ther¬†

2011;10:2298-2308. Published OnlineFirst September 16, 2011.

Updated version
¬† 
Supplementary
Material
¬† 

10.1158/1535-7163.MCT-11-0264
 

Access the most recent version of this article at:
doi:
¬† 
Access the most recent supplemental material at:
 
http://mct.aacrjournals.org/content/suppl/2011/09/16/1535-7163.MCT-11-0264.DC1.html
¬† 

Cited Articles
¬† 
Citing articles
¬† 

This article cites by 48 articles, 19 of which you can access for free at:
http://mct.aacrjournals.org/content/10/12/2298.full.html#ref-list-1
 
¬† 
This article has been cited by 12 HighWire-hosted articles. Access the articles at:
http://mct.aacrjournals.org/content/10/12/2298.full.html#related-urls
 
¬† 

¬† 
¬† 

¬† 
¬† 

E-mail alerts
¬† 
Reprints and 
Subscriptions
¬† 
Permissions
¬† 

Sign up to receive free email-alerts

 related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
pubs@aacr.org
.
¬† 
To request permission to re-use all or part of this article, contact the AACR Publications Department at
.
permissions@aacr.org
¬† 

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Preclinical Development

Molecular
Cancer
Therapeutics

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor,
Simultaneously Suppresses Metastasis, Angiogenesis, and
Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan, Kyoko Yamaguchi, Yongchang Shi, Peiwen Yu, Fawn Qian,
Felix Chu, Frauke Bentzien, Belinda Cancilla, Jessica Orf, Andrew You, A. Douglas Laird, Stefan Engst,
Lillian Lee, Justin Lesch, Yu-Chien Chou, and Alison H. Joly

Abstract

The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is
important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF,
which is widely recognized as a key effector in angiogenesis and cancer progression. Dysregulation of the
MET/VEGF axis is found in a number of human malignancies and has been associated with tumorigenesis.
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor
2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor
pathobiology, including RET, KIT, AXL, and FLT3. Treatment with cabozantinib inhibited MET and VEGFR2
phosphorylation in vitro and in tumor models in vivo and led to signiÔ¨Åcant reductions in cell invasion in vitro. In
mouse models, cabozantinib dramatically altered tumor pathology, resulting in decreased tumor and
endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor
growth in breast, lung, and glioma tumor models. Importantly, treatment with cabozantinib did not increase
lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF
signaling that do not target MET. Collectively, these data suggest that cabozantinib is a promising agent
for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
Mol Cancer Ther; 10(12); 2298‚Äì308. √ì2011 AACR.

Introduction

The receptor tyrosine kinase MET is the only known
receptor for hepatocyte growth factor (HGF), and its
signaling activity is required for embryogenesis, cell pro-
liferation, survival, and motility (1). While MET and HGF
are found in low levels in normal adult tissues, their
expression is frequently dysregulated in a broad spectrum
of human tumors. Ectopic activation of MET promotes
tumor cell survival, growth, angiogenesis, invasion, and
metastasis (2, 3). In preclinical animal models, overexpres-
sion of MET and/or HGF has been shown to stimulate
tumorigenesis and metastasis (2, 4), whereas downregula-
tion of MET or HGF expression resulted in increased
apoptosis and decreased tumor growth and blood vessel
density (5, 6). Clinically, dysregulated expression of HGF

Authors' AfÔ¨Åliation: Exelixis, Inc., South San Francisco, California

Note: Supplementary material for this article is available at Molecular
Cancer Therapeutics Online (http://mct.aacrjournals.org/).

Corresponding Author: F. Michael Yakes, Exelixis, Inc., 210 East Grand
Ave, South San Francisco, CA 94083. Phone: 650-837-7253; Fax: 650-
837-8315; E-mail: myakes@exelixis.com

doi: 10.1158/1535-7163.MCT-11-0264
√ì2011 American Association for Cancer Research.

and/or MET has been observed in many different tumor
types, including glioma, melanoma, hepatocellular, renal,
gastric, pancreatic, prostate, ovarian, breast, and lung
cancers, and is often correlated with poor prognosis
(1, 7). Collectively, these observations strongly implicate
MET/HGF signaling in the pathogenesis of human cancer.
Induction of angiogenesis has been increasingly recog-
nized as a crucial step in tumor progression and is one of
the hallmarks of cancerous growth. Correspondingly, the
proangiogenic signaling molecule VEGF and its receptors
VEGFR1, VEGFR2, and VEGFR3 play key roles in tumor
development. HGF is also a potent angiogenic factor and
acts synergistically with VEGF to induce angiogenesis
(8, 9). The U.S. Food and Drug Administration-approved
VEGF pathway inhibitors bevacizumab, sunitinib, and
sorafenib have proven to be clinically important in the
treatment of many types of cancer, but their effects are
characterized by initial clinical beneÔ¨Åt lasting weeks or
months before the resumption of tumor growth and
progression (10‚Äì12). Preclinical studies have found that
while continuous VEGF pathway inhibition initially
slows tumor growth and trims tumor vasculature, this is
quickly followed by rapid revascularization and
increased tumor invasiveness (13). These observations
show that cancers have the capacity to develop resistance
to VEGF pathway‚Äìtargeted inhibition.

2298

Mol Cancer Ther; 10(12) December 2011

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Tumor cell evasion of VEGF pathway‚Äìtargeted inhibi-
tion may occur as a response to hypoxia. Under hypoxic
conditions, hypoxia-inducible factor 1a is upregulated,
resulting in increased expression of both VEGF and MET
(14, 15). These responses apparently allow the tumor cells
to compensate for the hypoxic environment through stim-
ulation of angiogenesis or migration away from the hyp-
oxic zone. Because VEGF pathway inhibition can result in
induction of hypoxia, it may also trigger upregulation of
MET expression, which may then stimulate tumor inva-
sion. Indeed, Shojaei and colleagues recently determined
that the MET pathway plays an important role in the
development of resistance to VEGF pathway inhibition
by sunitinib treatment (16). Recent studies have also
showed that the use of VEGFR inhibitors, such as sunitinib,
sorafenib, cediranib, or a VEGFR2-targeting antibody, can
result in the development of an aggressive tumor pheno-
type characterized by increased invasiveness and metas-
tasis and, in patients treated with cediranib, higher MET
expression levels (17‚Äì19). Therefore, targeting both arms of
the MET/VEGF axis simultaneously may critically disrupt
angiogenesis, tumorigenesis, and cancer progression.

Cabozantinib (XL184) is a potent inhibitor of MET and
VEGFR2 that also inhibits RET, KIT, AXL, and FLT3, all of
which have been implicated in tumor pathogenesis (20,
21). In this study, we report on the consequences of
cabozantinib treatment on angiogenesis, cellular invasion,
tumor growth, and metastasis. Collectively, these data
suggest that cabozantinib may provide enhanced efÔ¨Åcacy
by simultaneously targeting key pathways important to
tumor survival, metastasis, and angiogenesis.

Materials and Methods

Compounds

Cabozantinib (Fig. 1A) was synthesized as described in
US Patent 7579473 (WO 2005030140 A2; ref. 22). For in vitro
assays, 10 mmol/L cabozantinib was prepared in dimeth-
yl sulfoxide and serially diluted in the appropriate assay
media. For in vivo studies, cabozantinib was formulated in
sterile saline/10 mmol/L HCl or in water and adminis-
tered via oral gavage at 10 mL/kg (mice) or 2 mL/kg
(rats).

Kinase inhibition assays

The inhibition proÔ¨Åle of cabozantinib against a broad
panel of 270 human kinases was determined using lucif-
erase-coupled chemiluminescence, 33P-phosphoryl trans-
fer, or AlphaScreen technology (PerkinElmer). Recombi-
nant human full-length, glutathione S-transferase tag, or
histidine tag fusion proteins were used, and half maximal
inhibitory concentration (IC50) values were determined by
measuring phosphorylation of peptide substrate poly
(Glu, Tyr) at ATP concentrations at or below the K
m for
each respective kinase. The mechanism of kinase inhibi-
tion was evaluated using the AlphaScreen Assay by
determining the IC50 values over a range of ATP
concentrations.

Antimetastatic and Antiangiogenic Effects of Cabozantinib

Cell lines

A431, B16F10, C6, H441, H69, Hs746T, HT1080, MS1,
PC3, SNU-1, SNU-5, SNU-16, and U87MG cells were
purchased from the American Type Culture Collection,
BaF3 cells were purchased from the German Resource
Center for Biological Material (DSMZ), and HMVEC-L
cells were purchased from BioWhitttaker Technologies.
MDA-MB-231 cells were a gift from Georgetown Univer-
sity School of Medicine, Washington, DC. No further
authentication was done on these lines. Cell lines were
passaged for less than 3 months and maintained in either
Dulbecco‚Äôs ModiÔ¨Åed Eagle‚Äôs Media (DMEM) or RPMI-
1640 media supplemented with 10% FBS, 1% penicillin-

streptomycin, and 1% nonessential amino acids at 37
C in
5% CO2. Where indicated, assays were conducted using
parental cell lines stably transfected with expression vec-
tors encoding kinases of interest.

Inhibition of receptor phosphorylation

Receptor phosphorylation of MET, VEGFR2, AXL, FLT3,
and KIT were, respectively, assessed in PC3, HUVEC,
MDA-MB-231, FLT3-transfected BaF3, and KIT-transfected
MDA-MB-231 cells. Cells were serum starved for 3 to
24 hours, then incubated for 1 to 3 hours in serum-free
medium with serially diluted cabozantinib before
10-minute stimulation with ligand: HGF (100 ng/mL),
VEGF (20 ng/mL), SCF (100 ng/mL), or ANG1
(300 ng/mL). All ligands were purchased from R&D
Systems. Receptor phosphorylation was determined either
by ELISA using speciÔ¨Åc capture antibodies and quantita-
tion of total phosphotyrosine (Zymed, Inc.) or immuno-
precipitation and Western blotting with speciÔ¨Åc antibodies
and quantitation of total phosphotyrosine (4G10; UpState
Biotechnology). Total protein served as loading controls.

Endothelial cell tubule formation assays

Human microvascular endothelial cells (HMVEC)
were mixed with serially diluted cabozantinib, then
immediately added to cultures of normal human diploid
Ô¨Åbroblasts in the presence or absence of 60 ng/mL VEGF
for 7 days. Conditioned media from MDA-MB-231, A431,
HT1080, and B16F10 cells were also used as a source of
secreted growth factors. Following Ô¨Åxation, tubule for-
mation was detected using the endothelial cell marker
CD31 (clone WM59; BD Biosciences) and visualized with
an immunoperoxidase detection system (Artisan AEC
Detection Kit; Dako). Digital images were captured using
an inverted microscope (20), and total tube length was
quantitated with Metamorph (Molecular Devices).

Invasion and migration assays

B16F10 cells (2  105) were seeded onto 0.8 mm mem-
branes in the upper chambers of a 96-well Transwell plate
in the absence or presence of Matrigel (BD Pharmingen;
BD Biosciences). Cells were incubated with serially dilut-
ed cabozantinib in DMEM/0.1% FBS. The lower chambers
contained HGF (50 ng/mL) and the appropriate concen-
tration of cabozantinib. After 24 hours, cells were

www.aacrjournals.org

Mol Cancer Ther; 10(12) December 2011

2299

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Yakes et al.

Figure 1. Cabozantinib inhibits
VEGF-induced tubule formation
and HGF-stimulated migration and
invasion. A, chemical structure of
cabozantinib. B, HMVEC-L cells
were cocultured with human diploid
Ô¨Åbroblasts for 7 days in the
presence of VEGF (60 ng/mL) and
cabozantinib, and tubule formation
relative to VEGF-treated cells
determined by immunostaining for
the endothelial marker CD31. A
representative image
approximating the cabozantinib
dose-response IC50 is shown (4.6
nmol/L). C, B16F10 cells were
seeded in the upper chambers of a
96-well Transwell plate and
incubated with cabozantinib,
whereas the corresponding lower
chambers contained HGF
(50 ng/mL) and cabozantinib.
Inhibition of migration was
determined 24 hours later. D,
B16F10 cells were seeded in the
upper chambers of a 96-well
Transwell plate coated with Matrigel
and incubated with cabozantinib,
whereas the corresponding lower
chambers contained HGF (50 ng/
mL) and cabozantinib. Inhibition of
invasion was determined 24 hours
later.

recovered from the lower chamber using Accutase (Inno-
vative Cell Technologies). Cell suspensions were incubat-
ed with calcein AM (Molecular Probes; Invitrogen) and
digital images captured with a Ô¨Çuorescence microscope.
MS1 mouse endothelial cells were plated in 96-well plates
coated with Ô¨Åbronectin. A cell-free zone was created that
was followed by treatment with serially diluted cabozan-
tinib and 30 ng/mL VEGF or 30 ng/mL HGF. After 20
hours, cell migration was determined from digitally cap-
tured images.

Cellular proliferation

Cells were seeded in triplicate overnight in media con-
taining 10% FBS. The next day, cells were treated with
serial dilutions of cabozantinib for 48 hours, followed by
analysis of proliferation using Cell Proliferation ELISA,
BrdUrd (Roche Applied Science).

In vivo inhibition of receptor phosphorylation

Female nu/nu mice (Taconic) were housed according to
the Exelixis Institutional Animal Care and Use Committee
guidelines. H441 cells (3  106) were implanted intrader-
mally into the hind Ô¨Çank and when tumors reached
approximately 150 mg, tumor weight was calculated
using the formula: (tumor volume ¬º length (mm) 
width2 (mm2)]/2, mice were randomized (n ¬º 5 per
group) and orally administered a single 100 mg/kg dose
of cabozantinib or vehicle. Tumors were collected at the
indicated time points. Pooled tumor lysates were sub-
jected to immunoprecipitation with anti-MET (SC161;
Santa Cruz Biotechnology) and Western blotting with
anti-phosphotyrosine MET (pY1230/34/35; BioSource
International). After blot stripping, total MET was quan-
titated as a loading control. In a separate experiment,
naive mice (n ¬º 5 per group) were administered a single

2300

Mol Cancer Ther; 10(12) December 2011

Molecular Cancer Therapeutics

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

100 mg/kg dose of cabozantinib or vehicle, followed by
intravenous administration of HGF (10 mg per mouse) 10
minutes before liver collection. Analysis of MET phos-
phorylation in liver lysates was as described above. In a
separate experiment, naive mice (n ¬º 5 per group) were
administered a single 100 mg/kg dose of cabozantinib or
vehicle, followed by intravenous administration of VEGF
(10 mg per mouse) 30 minutes before lung collection.
Pooled lung lysates were subjected to immunoprecipita-
tion with FLK1 (SC6251; Santa Cruz Biotechnology) and
Western blotting with anti-phosphotyrosine (4G10,
Upstate Biotechnology). After blot stripping, total FLK1
was quantitated as a loading control.

Immunohistochemistry
MDA-MB-231 cells (1  106) were implanted subcuta-
neously into the uncleared mammary fat pad of nu/nu
mice. When the tumors reached approximately 100 mg
(12 days after implantation), mice were randomized (n¬º 8
per group) and orally administered cabozantinib (100
mg/kg) or saline vehicle once daily for 4 days. Body
weights were collected daily. Four hours before tumor
harvest, animals were injected intraperitoneally with 60
mg/kg pimonidazole to facilitate visualization of tumor
hypoxia. Tumors were resected at 4 and 8 hours after the
Ô¨Årst dose and 4 hours after the second, third, and fourth
doses, respectively, snap frozen in optimum cutting
temperature (Miles, Inc.) and processed for staining
for hypoxia (Hypoxyprobe-1; Chemicon), vascularity
[endothelial cell marker MECA-32 (#550563, BD Bio-
sciences)], and proliferation [Ki67 (#RM-9106-S; Lab
Vision)]. Apoptosis [terminal deoxynucleotidyl transfer-
ase‚Äìmediated dUTP nick end labeling (TUNEL)] deter-
mination was carried out using an In Situ Cell Death
Detection Kit (Roche). Digital Ô¨Çuorescent images were
captured using a Zeiss Axioskop 2 with AxioVision (Carl
Zeiss MicroImaging LLC) image analysis software. One to
5 nonoverlapping representative Ô¨Åelds were captured at
5 (hypoxia, TUNEL, Ki67), 100 (MECA-32), and 400
(endothelial cell death) magniÔ¨Åcation and quantiÔ¨Åed
using Metamorph (Molecular Devices).

Solid tumor efÔ¨Åcacy studies
On day 0 in nu/nu mice, cells were inoculated
intradermally into the hind Ô¨Çank (3  106 cells, H441) or
subcutaneously into a noncleared mammary fat pad
(1  106 cells, MBA-MB-231). When tumors reached
approximately 100 mg (12‚Äì14 days after implantation),
mice were randomized (n ¬º 10 per group) and treated
orally once daily for 14 days with cabozantinib or saline
vehicle. In a separate study, MDA-MB-231 tumors were
allowed to reach approximately 500 or 1,000 mg before
randomization and initiation of cabozantinib treatment.
On day 0 in female Wistar rats (Charles River Laborato-
ries), C6 cells (5  106) were inoculated subcutaneously
into the hind Ô¨Çank. When the tumors reached approxi-
mately 250 mg (3‚Äì4 days postimplantation), rats were
randomized (n ¬º 8 per group) and treated orally once

Antimetastatic and Antiangiogenic Effects of Cabozantinib

daily for 12 days with cabozantinib or water vehicle.
Body weights were collected daily, and tumor weights
were collected twice weekly. Percentage of tumor growth
inhibition/regression values were expressed as follows:
1   [(mean treated tumor weight on the Ô¨Ånal day   mean
tumor weight on day 0)/(mean vehicle tumor weight on
the Ô¨Ånal day   mean tumor weight on day 0)]  100.
Statistical analysis of cabozantinib-treated tumors versus
vehicle-treated tumors or versus predose tumors was done
by one-way ANOVA with signiÔ¨Åcance deÔ¨Åned as P < 0.05.
Blood was collected 4 hours after the Ô¨Ånal dose, and plasma
was prepared to determine cabozantinib concentrations.

Experimental metastasis
On day 1, MDA-MB-231 cells (1  106) were implanted
via tail vein injection into nu/nu mice that was immedi-
ately followed by randomization (n ¬º 12‚Äì15 per group)
and oral treatment with cabozantinib (60 mg/kg), suniti-
nib (120 mg/kg), or vehicle for 28 days. On day 28, lungs
were perfused in situ with India ink solution (15% in PBS),
resected, and lung wet weights immediately captured.
Lungs were destained and Ô¨Åxed in Fekete‚Äôs buffer (70%
ethanol, 4% formaldehyde, glacial acetic acid; 20:2:1) for
72 hours, then transferred to 70% ethanol until image
acquisition and analysis as previously described (23).
BrieÔ¨Çy, each lung was separated into 5 lobes, and ventral
and dorsal surface aspects were digitally captured with
lobes submerged under water. Images were analyzed by
DeÔ¨Åniens Developer XD to assess lung tumor foci counts.
The number of tumor foci for ventral and dorsal lung
surface aspects were obtained after applying size thresh-
old parameters to exclude foci with diameters below
4 pixels from analysis (23). As the tumor foci data did
not pass the normality and Gaussian distribution tests,
statistical analysis was conducted via nonparametric
ANOVA (Kruskal‚ÄìWallis analysis).

Results

Cabozantinib inhibits kinase activity

The selectivity of cabozantinib (Fig. 1A) was proÔ¨Åled
against a protein kinase panel of approximately 270
human kinases. Cabozantinib is a potent inhibitor of MET
and VEGFR2 with IC50 values of 1.3 and 0.035 nmol/L,
respectively (Table 1). MET-activating kinase domain
mutations Y1248H, D1246N, or K1262R were also inhib-
¬º 3.8, 11.8, and 14.6 nmol/L,
ited by cabozantinib (IC50
respectively). Cabozantinib displayed strong inhibition of
several kinases that have also been implicated in tumor
pathobiology, including KIT, RET, AXL, TIE2, and FLT3
¬º 4.6, 5.2, 7, 14.3, and 11.3 nmol/L, respectively).
(IC50
Kinases not potently inhibited include RON, EGFR,
IGFR1, and EphA4/B4. In cellular assays, cabozantinib
inhibited phosphorylation of MET and VEGFR2, as well
as KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5,
and 42 mmol/L, respectively.

IC50 determinations

con-
centrations of ATP revealed that cabozantinib is an

conducted at various

www.aacrjournals.org

Mol Cancer Ther; 10(12) December 2011

2301

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Yakes et al.

Table 1. In vitro kinase inhibition proÔ¨Åle of cabozantinib

Kinase

VEGFR2
MET
MET (Y1248H)
MET (D1246N)
MET (K1262R)
RET
TIE2
AXL
FLT3
KIT
RON

IC50  SD,a nmol/L
0.035  0.01
1.3  1.2
3.8
11.8
14.6
5.2  4.3
14.3  1.1
7
11.3  1.8
4.6  0.5
124  1.2

Enzyme concentration, nmol/L

ATP concentration, mmol/L

Assay

0.05
10
13
12
12
15
15
TBD
0.5
1
60

3
1
1
1
1
2
5
TBD
1
3
1

A
C
C
C
C
C
R
TBD
C
A
C

Abbreviations: A, AlphaScreen; C, Coupled luciferase; R, radiometric; TBD, to be determined.
aMean  SD of at least 3 independent determinations.

ATP-competitive inhibitor of MET, VEGFR2, TIE2, and
FLT3 (data not shown). Kinetic constants for binding to
MET and VEGFR2 show tight but reversible binding
(Supplementary Table S1).

Cabozantinib inhibits endothelial cell tubule
formation in vitro

HMVEC cells were incubated with VEGF in the pres-
ence of cabozantinib and tubule formation visualized by
immunostaining for CD31. Cabozantinib inhibited tubule
formation with an IC50 value of 6.7 nmol/L (Fig. 1B) with
no evidence of cytotoxicity, showing that cabozantinib
exerts an antiangiogenic rather than cytotoxic effect.
Cabozantinib also inhibited tubule formation in response
to conditioned media derived from cultures of MDA-MB-
¬º 4.1 nmol/L),
231 (IC50
¬º 4.7
HT1080 (IC50
nmol/L) cells, suggesting that secreted tumor cell‚Äì
derived proangiogenic growth factors are unable to cir-
cumvent inhibition of tubule formation by cabozantinib.

¬º 7.7 nmol/L), and B16F10 (IC50

¬º 5.1 nmol/L), A431 (IC50

Cabozantinib inhibits cellular migration and
invasion

We have previously shown that HGF promotes MET
phosphorylation in B16F10 cells and stimulates migra-
tion and invasion (24). Cabozantinib potently inhibited
¬º 31 nmol/L; Fig. 1C) and
HGF-induced migration (IC50
¬º 9 nmol/L; Fig. 1D) of B16F10 cells.
invasion (IC50
VEGF- and HGF-mediated migration of proangiogenic
murine MS1 endothelial cells (25) were also sensitive to
cabozantinib with IC50 values of 5.8 and 41 nmol/L,
respectively.

Cabozantinib inhibits tumor cell proliferation in a
variety of tumor types

The effect of cabozantinib on proliferation was eval-
uated in a number of human tumor cell lines. SNU-5
and Hs746T cells harboring ampliÔ¨Åed MET (26) were

¬º 19 and 9.9
the most sensitive to cabozantinib (IC50
nmol/L, respectively); however, SNU-1 and SNU-16
cells lacking MET ampliÔ¨Åcation were more resistant
¬º 5,223 and 1,149 nmol/L, respectively). MDA-
(IC50
MB-231 and U87MG cells exhibited comparable levels
¬º 6,421 and 1,851
of sensitivity to cabozantinib (IC50
nmol/L, respectively), whereas H441, H69, and PC3 cell
lines were the least sensitive to cabozantinib with IC50
values of 21,700, 20,200, and 10,800 nmol/L, respec-
tively.
In addition, BaF3 cells expressing human
FLT3-ITD, an activating mutation in acute myelogenous
¬º 15
leukemia (27), were sensitive to cabozantinib (IC50
nmol/L) when compared with wild-type BaF3 cells
(IC50

¬º 9,641 nmol/L).

Cabozantinib inhibits MET and VEGFR2
phosphorylation in vivo

A single 100 mg/kg oral dose of cabozantinib resulted
in inhibition of phosphorylation of MET 2 to 8 hours
postdose in H441 tumors that harbor constitutively phos-
phorylated MET (Fig. 2A). This result is consistent with
data showing the sensitivity of these cells to inhibitors
selective for MET and MET knockdown by siRNA (28, 29).
This effect was reversible, as MET phosphorylation
returned to basal levels by 48 hours after treatment. In
separate experiments, cabozantinib inhibited in vivo stim-
ulation of MET phosphorylation by HGF in liver hepato-
cytes (Fig. 2B) and VEGF-stimulated phosphorylation of
FLK1 (Fig. 2C) with inhibition of both targets sustained
through 8 hours postdose. Furthermore, cabozantinib
eliminated endogenous levels of phosphorylated FLK1
that are present in the absence of VEGF stimulation.
Plasma concentrations of cabozantinib (Supplementary
Table S2) associated with maximal and sustained inhibi-
tion of MET and FLK1 were 17 to 34 mmol/L, greater than
3-fold above the MET cellular phosphorylation, VEGF
tubule formation, and HGF invasion IC50 values
described above.

2302

Mol Cancer Ther; 10(12) December 2011

Molecular Cancer Therapeutics

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Antimetastatic and Antiangiogenic Effects of Cabozantinib

Figure 2. Cabozantinib treatment
results in inhibition of
phosphorylation of MET in tumor
and liver tissue and
phosphorylation of FLK1 in lung
tissue following a single oral dose.
A, mice bearing H441 tumors were
administered a single oral dose of
cabozantinib (100 mg/kg) or water
vehicle, and levels of
phosphorylated and total MET in
tumor lysates were determined. B,
naive mice were administered a
single dose of cabozantinib
(100 mg/kg) or water vehicle. Ten
minutes before harvest, mice were
intravenously administered HGF
(10 mg per animal), and levels of
phosphorylated and total MET in
liver lysates were determined.
C, naive mice were administered a
single dose of cabozantinib
(100 mg/kg) or water vehicle. Thirty
minutes before harvest, mice were
intravenously administered VEGF
(10 mg per animal), and levels of
phosphorylated and total FLK1 in
lung lysates were determined.
Representative Western blot
images are shown.

Cabozantinib disrupts tumor vasculature and
promotes tumor and endothelial cell death

antiangiogenic-sensitive MDA-MB-231

To examine the effect of cabozantinib on tumor vascu-
lature,
cells
expressing MET and VEGF were used (28, 30). Tumor-
bearing animals were administered a 100-mg/kg oral
dose, and tumors were collected 4 and 8 hours after the
Ô¨Årst dose and 4 hours after the consecutive second, third,
and fourth doses. Vehicle-treated tumors exhibited low
levels of hypoxia (1%) and TUNEL (0.5%), and high
levels of Ki67 (60%) and MECA-32 (20%), indicative of
viable, highly proliferative, and vascularized tumors
(data not shown). Cabozantinib signiÔ¨Åcantly increased
tumor hypoxia (13-fold; Fig. 3A) and apoptosis (TUNEL;
2.5-fold; Fig. 3B) at 8 and 4 hours after the Ô¨Årst and second
doses, respectively, when compared with vehicle-treated
tumors collected at the same time point. Concomitant
reductions in the proliferation marker Ki67 (19%; Fig.

3C) and the endothelial cell surface marker MECA-32
(12%; Fig. 3D) were also observed 8 hours after a single
dose. Progressive, marked changes in these endpoints
continued such that after the third dose, the number of
apoptotic and hypoxic cells were elevated 78- and 85-fold,
respectively, whereas marked reductions in Ki67 (55%)
and MECA-32 (75%) were also evident. Summarized
quantitative data are provided in Supplementary Table
S3. Despite these profound and progressive effects of
cabozantinib on tumor physiology, animals seemed
healthy with no visible signs of toxicity or loss of body
weight (data not shown).

The rapid decrease of MECA-32 prompted closer exam-
ination of tumor endothelial cell survival. Simultaneous
examination of TUNEL-, MECA-32-, and 4
,6-diamidino-
2-phenylindole‚Äìstained cells
revealed cabozantinib-
induced cell death not only in tumor cells but also in
endothelial cells in the tumor vasculature (Fig. 3E). Taken

0

www.aacrjournals.org

Mol Cancer Ther; 10(12) December 2011

2303

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Yakes et al.

Figure 3. Cabozantinib causes rapid
increases in tumor hypoxia (A) and
cell death (B) and decreases in
proliferation (C) and vascularity (D)
in MDA-MB-231 tumors. MDA-MB-
231 tumor-bearing mice were orally
administered cabozantinib (100
mg/kg) or vehicle once daily for 4
days. Tumors were resected 4 and 8
hours after the Ô¨Årst dose and 4
hours after the second, third, and
fourth doses and processed for
immunoÔ¨Çuorescence evaluation of
tumor hypoxia, apoptosis (TUNEL),
proliferation (Ki67), and tumor
vascularity (MECA-32). Digital
images were captured at 5
(hypoxia, TUNEL, and Ki67) and
100 (MECA-32) magniÔ¨Åcations. E,
additional tumor sections were
processed for simultaneous
evaluation of viable tumor cells
(blue), tumor endothelial cells (red),
and cell death (green). Arrows
indicate regions of endothelial cell
death (yellow color resulting from
red and green overlay). Digital
images were captured at 400
magniÔ¨Åcation.

to vehicle-treated control tumors (Supplementary Fig.
S1A). In a similar but separate study with larger MDA-
MB-231 tumors, a 10-mg/kg dose resulted in induction of
stable disease that was independent of initial tumor size
(Fig. 4B), whereas a 60-mg/kg dose resulted in signiÔ¨Åcant
tumor regression of both 500-mg (37%, P ¬º 0.0003) and
1,000-mg (45%, P ¬º 0.0001) tumors. Cabozantinib inhib-
ited growth of H441 tumors at all doses (P < 0.001), with
dose-dependent inhibition observed for the 10- and 30-
mg/kg doses (Fig. 4C). The 60-mg/kg dose resulted in
signiÔ¨Åcant tumor regression (33%, P < 0.005) when com-
pared with predose tumor weights. As elevated MET
expression has been detected in human gliomas and
implicated in glioma cell growth (29, 31), the antitumor
effect of cabozantinib in the MET-expressing rat C6 glio-
ma cell line (32) was determined. Cabozantinib inhibited
tumor growth (P < 0.001) for all doses when compared
with vehicle-treated tumors (Fig. 4D). Moreover, the
3- and 10-mg/kg doses resulted in signiÔ¨Åcant tumor
regression (62 and 85%, P < 0.0001) when compared with
predose tumor weights. In a separate experiment, a single
10-mg/kg dose resulted in C6 tumor growth inhibition

together, these results show that cabozantinib disrupts
tumor vasculature by inducing endothelial cell death that
negatively impacts tumor viability.

Cabozantinib inhibits tumor growth in a
dose-dependent manner

The in vivo efÔ¨Åcacy of cabozantinib was evaluated in
human tumor models in rodents over a period of time that
corresponded to exponential tumor growth of each mod-
el. Cabozantinib treatment resulted in signiÔ¨Åcant tumor
growth inhibition of MDA-MB-231 tumors (P < 0.001) for
all doses when compared with vehicle-treated tumors
(Fig. 4A). Dose-dependent inhibition was observed for
the 3- and 10-mg/kg doses (P < 0.01). At the 30- and 60-
mg/kg doses, cabozantinib induced stable disease. Con-
tinuous treatment at these doses was associated with
plasma concentrations of 9,000 to 16,000 nmol/L, which

was 2-fold above IC50 values for cellular proliferation

and tubule formation with MDA-MB-231 conditioned
media. A single 100 mg/kg dose resulted in sustained
MDA-MB-231 tumor growth inhibition for approximately
8 days after which tumors began growing at a rate similar

2304

Mol Cancer Ther; 10(12) December 2011

Molecular Cancer Therapeutics

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Antimetastatic and Antiangiogenic Effects of Cabozantinib

Figure 4. Cabozantinib inhibits
tumor growth and promotes tumor
regression. Animals bearing
established MDA-MB-231 (A and
B), H441 (C), and C6 (D) tumors
were orally administered once daily
vehicle (&) or cabozantinib at
1 mg/kg (D), 3 mg/kg (r), 10 mg/kg
(&), 30 mg/kg (*), or 60 mg/kg (*)
for 12 to 14 days, depending on the
model. Tumor weights were
determined twice weekly. Data
points represent the mean tumor
weight (in milligrams) and SE for
each treatment group. Arrows in B
represent onset of cabozantinib
treatment.

that was sustained during a 15-day observation period
(Supplementary Fig. S1B). On a body weight dosage basis,
cabozantinib plasma exposures ranged from 6- to 10-fold
higher in rats than in mice (Supplementary Table S4),
which accounts for lower doses inducing tumor growth
inhibition/regression in rats than in mice. Subchronic
administration of cabozantinib was well tolerated in mice
and rats with no signs of toxicity, as determined by stable
and/or increasing body weights during the treatment
period (Supplementary Fig. S1C and S1D).

Cabozantinib does not promote metastasis following
intravenous tumor cell inoculation

The impact of cabozantinib on metastasis to that of
VEGFR2-targeting therapies, known to promote metas-
tasis in preclinical models (17), was investigated. Imme-
diately following intravenous injection of MDA-MB-231
cells into mice, oral cabozantinib or sunitinib treatment
was initiated and continued once daily for 28 days.
Examination of intact lungs from cabozantinib-treated
mice revealed no apparent difference in lung surface
tumor burden when compared with lungs from vehicle-
treated control animals (Fig. 5A); however, lungs from
sunitinib-treated animals displayed an apparent

increase in tumor burden. Quantitation of tumor foci
per lobe surface revealed no statistical difference
in the number of foci for vehicle- and cabozantinib-
treated mice (56 vs. 64 foci/lobe surface, P > 0.05) and a
2-fold increase in tumor foci for sunitinib-treated mice
(109 foci/lobe surface, P < 0.001; Fig. 5B). Additional
evidence of inhibition of metastasis was conÔ¨Årmed
by lack of a signiÔ¨Åcant increase (P > 0.05) in whole lung
wet weights in cabozantinib-treated animals (Fig. 5C).
Cabozantinib treatment was well tolerated as deter-
mined by stable body weights throughout the 28-day
treatment period.

Discussion

The MET signaling pathway has been shown to be
important in tumor growth, survival, and metastasis and
acts synergistically with VEGF to promote angiogenesis
(8, 9). Both MET and VEGF are found to be dysregulated in
many tumor types, resulting in tumor angiogenesis and
tumor cell proliferation and invasion. Because of the
synergistic effects of MET and VEGFR signaling, inhibit-
ing both arms of the MET/VEGF axis may offer signiÔ¨Åcant
beneÔ¨Åt over targeting either pathway individually.

www.aacrjournals.org

Mol Cancer Ther; 10(12) December 2011

2305

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Yakes et al.

Figure 5. Treatment with
cabozantinib does not accelerate
tumor growth in an experimental
model of metastasis. On day 1,
MDA-MB-231 cells (1  106) were
injected intravenously into the tail
vein of female mice, which was
immediately followed by daily oral
administration of vehicle,
cabozantinib (60 mg/kg), or
sunitinib (120 mg/kg) for 28 days. A,
representative images showing
surface tumor foci from the
indicated treatment groups on day
28 posttumor cell implantation. B,
scatter plot depicting the number of
tumor foci following 28 days of
cabozantinib, sunitinib, or vehicle
treatment. The number of tumor foci
in cabozantinib-treated lungs was
not signiÔ¨Åcantly different when
compared with the number of tumor
foci in vehicle-treated lungs
(P > 0.05). C, whole lung wet
weights on day 28 posttumor cell
implantation. , P < 0.001.

Importantly,

In tumor cells, inappropriate activation of MET occurs
through overexpression of wild-type MET or its ligand
HGF or as a result of activating mutations in the gene
encoding MET.
cabozantinib potently
inhibits both wild-type MET and MET with activating
mutations, such as those frequently found in hereditary
papillary renal and hepatocellular carcinomas (33, 34).
Further evidence for the potent activity of cabozantinib
comes from cell proliferation studies, where it robustly
inhibited cell lines known to be dependent on MET but not
cell lines known to be independent of MET.

As shown in this report, cabozantinib exhibits potent
and reversible inhibition of its targets, leading to disrup-
tion of cellular processes that have been implicated in
angiogenesis and tumorigenesis, including migration and
tubule formation. This translates into profound changes in
tumor physiology, including widespread endothelial and
tumor cell apoptosis, disruptions in tumor vasculature,
and increased hypoxia. Subchronic treatment with cabo-
zantinib results in broad antitumor efÔ¨Åcacy, and in some
models, tumor regression; however, a single dose exhibits
antitumor efÔ¨Åcacy for approximately 8 to 15 days in the
models examined.

We used a variety of tumor models that are driven by
diverse mechanisms. H441 cells overexpress constitutive-
ly active MET as well as activated EGFR, HER2, and HER3
(35). C6 rat glioma cells overexpress MET and are PTEN
deÔ¨Åcient (32, 36). While MDA-MB-231 cells do not over-
express MET, they are responsive to HGF and also harbor
mutationally activated forms of RAS and RAF (37, 38).

None of these cell lines are known to be strictly addicted to
or dependent on signaling through MET for proliferation,
consistent with their relative resistance to cabozantinib in
vitro. However, our studies with cabozantinib suggest that
the observed antitumor efÔ¨Åcacy is the result of mechan-
isms affecting tumor angiogenesis and the blockade of
invasive tumor growth rather than the result of directly
targeting cellular proliferation.

One of the limitations of VEGF-targeted therapies has
been a lack of enduring clinical beneÔ¨Åt. Bergers and
Hanahan recently theorized that tumor cells may develop
resistance to antiangiogenic therapies through adaptive
mechanisms such as upregulation of alternative proan-
giogenic signaling pathways and enhancement of metas-
tasis (39). Indeed, VEGFR inhibitors such as sunitinib,
sorafenib, cediranib, VEGFR2-targeting antibodies, and
neutralizing antimurine VEGF antibodies have all been
observed to increase the invasiveness and/or metastatic
potential of tumors (17, 18, 19, 40). Ebos and colleagues
hypothesized that treatment with sunitinib may lead to
upregulation of cytokines that promote metastasis (17),
and recent studies have suggested that the MET/HGF
pathway is important for proangiogenic and prometa-
static signaling in the context of VEGF inhibition
(16, 19, 40). In light of these observations, it is interesting
that our results show that cabozantinib produces potent
antitumor and antiangiogenic effects without increasing
tumor metastatic potential, unlike treatment with suniti-
nib, suggesting that targeting MET and VEGFR2 simul-
taneously may cut off metastatic escape pathways. A

2306

Mol Cancer Ther; 10(12) December 2011

Molecular Cancer Therapeutics

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

recent study using RIP-Tag2 transgenic mice similarly
showed that treatment with cabozantinib resulted in more
extensive tumor shrinkage and decreased tumor invasive-
ness and metastasis than treatment with vehicle or anti-
VEGF antibody. Strikingly, in that study, all of the mice
treated with cabozantinib survived until the experiment
ended at 20 weeks, whereas none of the vehicle- or anti-
VEGF antibody‚Äìtreated mice survived to that endpoint
(40). Together, these data suggest that inhibiting MET and
VEGFR2 with cabozantinib effectively blocks the devel-
opment of MET-driven evasive resistance seen with
agents targeting the VEGF pathway alone, thereby pro-
viding a more sustained antitumor effect.

Our results provide support for testing cabozantinib
in a broad variety of tumors where MET activation has
been implicated and/or VEGF pathway inhibitors have
shown efÔ¨Åcacy. Cabozantinib is currently being studied
in clinical trials in a number of tumor types, including
medullary and differentiated thyroid, prostate, ovarian,
non‚Äìsmall cell
lung, hepatocellular, renal cell, and
breast cancers, as well as melanoma and glioblastoma
(41). In clinical trials, cabozantinib was generally well
tolerated, with promising clinical activity and response
in multiple tumor types (42‚Äì49). The data presented

References
1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met,
metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:
915‚Äì25.

2. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness
and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth
factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A
1994;91:4731‚Äì5.

3. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al.
Targeting the tumor and its microenvironment by a dual-function
decoy Met receptor. Cancer Cell 2004;6:61‚Äì73.

4. Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G,
et al. The MET oncogene drives a genetic programme linking cancer to
haemostasis. Nature 2005;434:396‚Äì400.

5. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M,
et al. Diverse tumorigenesis associated with aberrant development in
mice overexpressing hepatocyte growth factor/scatter factor. Proc
Natl Acad Sci U S A 1997;94:701‚Äì6.

6. Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al. In
vivo targeting of SF/HGF and c-met expression via U1snRNA/ribo-
zymes inhibits glioma growth and angiogenesis and promotes apo-
ptosis. FASEB J 2002;16:108‚Äì10.

7. Christensen JG, Burrows J, Salgia R. c-Met as a target for human
cancer and characterization of inhibitors for therapeutic intervention.
Cancer Lett 2005;225:1‚Äì26.

8. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, et al. Hepatocyte
growth factor enhances vascular endothelial growth factor-induced
angiogenesis in vitro and in vivo. Am J Pathol 2001;158:1111‚Äì20.

9. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R,
et al. Potentiated angiogenic effect of scatter factor/hepatocyte
growth factor via induction of vascular endothelial growth factor: the
case for paracrine ampliÔ¨Åcation of angiogenesis. Circulation 1998;97:
381‚Äì90.

10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,
Heim W, et al. Bevacizumab plus irinotecan, Ô¨Çuorouracil, and leucov-
orin for metastatic colorectal cancer. N Engl J Med 2004;350:2335‚Äì42.
11. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM,
Oudard S, et al. Overall survival and updated results for sunitinib

Antimetastatic and Antiangiogenic Effects of Cabozantinib

here show that cabozantinib has potent antimetastatic,
antitumor, and antiangiogenic activity in preclinical
models, and they support the ongoing evaluation of
the clinical activity of cabozantinib in patients with a
variety of cancers.

Disclosure of Potential ConÔ¨Çicts of Interest

All authors are employees of Exelixis, Inc.

Acknowledgments

The authors thank Dana Aftab and Peter Lamb for critical reading of the
manuscript, Barbara Sennino for assistance with the migration images, and
Cheryl Chun of BlueMomentum.

Grant Support

The Ô¨Ånancial support was provided by Exelixis, Inc. The funding for

BlueMomentum was provided by Exelixis.

The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.

Received April 7, 2011; revised September 9, 2011; accepted September

13, 2011; published OnlineFirst September 16, 2011.

compared with interferon alfa in patients with metastatic renal cell
carcinoma. J Clin Oncol 2009;27:3584‚Äì90.

12. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al.
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med
2007;356:125‚Äì34.

13. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by
evasion of antiangiogenic targeting of VEGF signaling in late-stage
pancreatic islet tumors. Cancer Cell 2005;8:299‚Äì309.

14. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. Induction of hepatocyte
growth factor activator gene expression under hypoxia activates the
hepatocyte growth factor/c-Met system via hypoxia inducible factor-1
in pancreatic cancer. Cancer Sci 2008;99:1341‚Äì7.

15. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S,
Comoglio PM. Hypoxia promotes invasive growth by transcription-
al activation of
the met protooncogene. Cancer Cell 2003;3:
347‚Äì61.

16. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA,
et al. HGF/c-Met acts as an alternative angiogenic pathway in suni-
tinib-resistant tumors. Cancer Res 2010;70:10090‚Äì100.

17. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG,
Kerbel RS. Accelerated metastasis after short-term treatment with a
potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232‚Äì9.
18. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vi~nals F, et al.
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell 2009;15:
220‚Äì31.

19. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi
L, et al. Glioblastoma recurrence after cediranib therapy in patients:
lack of "rebound" revascularization as mode of escape. Cancer Res
2011;71:19‚Äì28.

20. Castellone MD, Carlomagno F, Salvatore G, Santoro M. Receptor
tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endo-
crinol Metab 2008;22:1023‚Äì38.

21. Tmar J, D‚Ç¨ome B. Antiangiogenic drugs and tyrosine kinases. Anti-

cancer Agents Med Chem 2008;8:462‚Äì9.

22. Bannen LC, Chan DS, Forsyth TP, Khoury RG, Leahy JW, Mac MB,
Inc., assignee. c-Met modulators and

inventors; Exelixis,

et al.

www.aacrjournals.org

Mol Cancer Ther; 10(12) December 2011

2307

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

Published OnlineFirst September 16, 2011; DOI: 10.1158/1535-7163.MCT-11-0264 

Yakes et al.

methods of use. United States patent US 7579473. 2009Aug 25. [cited
2011 Aug 8]. Available
from: http://patents.justia.com/2009/
07579473.html.

23. Watts AM, Kennedy RC. Quantitation of tumor foci in an experimental
murine model using computer-assisted video imaging. Anal Biochem
1998;256:217‚Äì19.

24. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. Inhibition
of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880,
GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine
kinases. Cancer Res 2009;69:8009‚Äì16.

25. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, et al.
Oncogenic H-ras stimulates tumor angiogenesis by two distinct path-
ways. Proc Natl Acad Sci U S A 1997;94:861‚Äì6.

26. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald
H, et al. AmpliÔ¨Åcation of MET may identify a subset of cancers with
extreme sensitivity to the selective tyrosine kinase inhibitor PHA-
665752. Proc Natl Acad Sci U S A 2006;103:2316‚Äì21.

27. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton
AA, et al. The presence of a FLT3 internal tandem duplication in
patients with acute myeloid leukemia (AML) adds important prognostic
information to cytogenetic risk group and response to the Ô¨Årst cycle
of chemotherapy: analysis of 854 patients from the United Kingdom
Medical Research Council AML 10 and 12 trials. Blood 2001;98:
1752‚Äì9.

28. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, et al. ARQ
197, a novel and selective inhibitor of the human c-Met receptor
tyrosine kinase with antitumor activity. Mol Cancer Ther 2010;9:
1544‚Äì53.

29. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al.
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-
dependent phenotypes in vitro and exhibits cytoreductive antitumor
activity in vivo. Cancer Res 2003;63:7345‚Äì55.

30. Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L,
et al. Inhibition of vascular endothelial growth factor reduces angio-
genesis and modulates immune cell inÔ¨Åltration of orthotopic breast
cancer xenografts. Mol Cancer Ther 2009;8:1761‚Äì71.

31. Chu S, Yuan X, Li Z, Jiang P, Zhang J. C-Met antisense oligodeox-
ynucleotide inhibits growth of glioma cells. Surg Neurol 2006;65:
533‚Äì8.

32. Towner RA, Smith N, Doblas S, Tesiram Y, Garteiser P, Saunders D,
et al. In vivo detection of c-Met expression in a rat C6 glioma model. J
Cell Mol Med 2008;12:174‚Äì86.

33. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M,
et al. Novel mutations of the MET proto-oncogene in papillary renal
carcinomas. Oncogene 1999;18:2343‚Äì50.

34. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, et al. Somatic
mutations in the kinase domain of the Met/hepatocyte growth factor
receptor gene in childhood hepatocellular carcinomas. Cancer Res
1999;59:307‚Äì10.

35. Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm
DL, et al. Association of constitutively activated hepatocyte growth

factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in
non-small-cell lung cancer cells. Br J Cancer 2009;100:941‚Äì9.

36. Kubiatowski T, Jang T, Lachyankar MB, Salmonsen R, Nabi RR,
Quesenberry PJ, et al. Association of increased phosphatidylinositol
3-kinase signaling with increased invasiveness and gelatinase activity
in malignant gliomas. J Neurosurg 2001;95:480‚Äì8.

37. Trusolino L, Cavassa S, Angelini P, Ando M, Bertotti A, Comoglio PM,
et al. HGF/scatter factor selectively promotes cell invasion by increas-
ing integrin avidity. FASEB J 2000;14:1629‚Äì40.

38. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phos-
phatidylinositol-3-OH kinase or RAS pathway mutations in human
breast cancer cell lines. Mol Cancer Res 2007;5:195‚Äì201.

39. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic ther-

apy. Nat Rev Cancer 2008;8:592‚Äì603.

40. Sennino B, Naylor RM, Tabruyn SP, You W-K, Aftab DT, McDonald
DM. Reduction of tumor invasiveness and metastasis and prolonga-
tion of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met
by XL184. Mol Cancer Ther 2009;8(12 Suppl):A13.

41. Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R. XL-184, a
MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid
cancer, glioblastoma multiforme and NSCLC.
IDrugs 2010;13:
112‚Äì21.

42. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R,
et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor,
in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660‚Äì6
43. Wen PY, Prados M, Schiff D, Reardon DA, Cloughesy T, Mikkelsen T,
et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET,
VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB).
J Clin Oncol 28:15s, 2010 (suppl; abstr 2006).

44. Gordon MS, Vogelzang NJ, Schoffski P, Daud A, Spira AI, O'Keeffe BA,
et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of
a phase II randomized discontinuation trial (RDT) in patients (pts) with
advanced solid tumors. J Clin Oncol 29:15s, 2011 (suppl; abstr 3010).
45. Nechushtan H, Edelman G, Jerusalem G, Gordon M, Kluger HM,
Moussa A, et al. Phase 2 results of XL184 in a cohort of patients (pts)
with advanced melanoma. Eur J Cancer 2010;8:7. Abstract 398.

46. Hussain M, Smith MR, Sweeney C, Corn PG, ElÔ¨Åky A, Gordon MS, et al.
Cabozantinib (XL184) in metastatic castration-resistant prostate can-
cer (mCRPC): results from a phase II randomized discontinuation trial.
J Clin Oncol 29:15s, 2011 (suppl; abstr 4516).

47. Buckanovich RJ, Berger R, Sella A, Sikic BI, Shen X, Ramies DA, et al.
Activity of cabozantinib (XL184) in advanced ovarian cancer patients
(pts): results from a phase II randomized discontinuation trial (RDT). J
Clin Oncol 29:15s, 2011 (suppl; abstr 5008).

48. Yasenchak C, Nackaerts K, Awada A, Gadgeel SM, Hellerstedt B, Perry
MC, et al. Phase 2 results of XL184 in a cohort of patients (pts) with
advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2010;8:7.
Abstract 397.

49. Van Cutsem E, Su WC, Davis J, Haas N, Samuel TA, Tsao CJ, et al.
Phase 2 study of XL184 in a cohort of patients (pts) with hepatocellular
carcinoma (HCC). Eur J Cancer 2010;8:7. Abstract 408.

2308

Mol Cancer Ther; 10(12) December 2011

Molecular Cancer Therapeutics

Downloaded from 

mct.aacrjournals.org 

on July 10, 2013. ¬© 2011 American Association for Cancer Research. 

